 Satsuma Pharmaceuticals Inc NASDAQ: STSA will conduct a new Phase 3 efficacy trial for STS101 dihydroergotamine DHE nasal powder as an acute treatment option for migraine. The study will start in mid-2021, with topline data expected in the second half of 2022. 